IP Library Granted Patent US 8,969,543
Granted Patent B2
US 8,969,543 · App. 11/651,011 · Granted Mar 3, 2015

SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof

Inventors: Ji Hoon Jeong (Seoul, KR); Tae Gwan Park (Daejeon, KR); Sun-Hwa Kim (Daegu, KR)
Assignees: Bioneer Corporation; Samyang Biopharmaceuticals Corporation; Korea Advanced Institute of Science and Technology
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,969,543
App. No.
11/651,011
Granted
Mar 3, 2015
Kind
B2
Abstract

The present invention is related to hybrid conjugates formed by covalently bonding siRNA (small interfering RNA) molecules to hydrophilic polymers for improving stability of the siRNA molecules effective for delivering the siRNA in vivo, and polyelectrolyte complex micelles formed by ionic interactions between the conjugates and multifunctional cationic compounds. The siRNA-hydrophilic polymer conjugates and polyelectrolyte complex micelles derived therefrom can be used for improving stability of the siRNA molecules in vivo. Consequently, the delivery of siRNA molecules for therapeutic applications into cells can be facilitated, and the siRNA is still active even though a small dose of the siRNA is used.

Claims (12)

1. A polyelectrolyte complex micelle comprising an siRNA-hydrophilic polymer conjugate and a cationic compound, wherein an end of the siRNA in the siRNA-hydrophilic polymer conjugate is covalently linked to a hydrophilic polymer via cleavable linkage, wherein a polyelectrolyte complex micelle is formed, and wherein the cationic compound is a cationic lipid.

2. The polyelectrolyte complex micelle according to claim 1 , wherein the hydrophilic polymer is selected from the group consisting of polyethylene glycol, polyvinylpyrolidone, polyoxazolin and combinations thereof.

3. The conjugate according to claim 1 , wherein the covalent bond (X) is a non-cleavable linkage.

4. The conjugate according to claim 3 , wherein the non-cleavable linkage is an amide bond or phosphate bond.

5. The polyelectrolyte complex micelle according to claim 1 , wherein the cleavable linkage is selected from the group consisting of a disulfide bond, acid-cleavable linkage, ester bond, anhydride bond, biodegradable bond and enzyme-cleavable linkage.

6. The polyelectrolyte complex micelle according to claim 1 , wherein the 3′ end of the siRNA molecule in the siRNA-hydrophilic polymer conjugate is covalently linked to the hydrophilic polymer.

7. The polyelectrolyte complex micelle according to claim 1 , wherein the siRNA decreases expression of a gene selected from the group consisting of c-myc, c-myb, c-fos, c-jun, c-raf, and c-src.

8. A method of preparing the siRNA-hydrophilic polymer conjugate of claim 1 , the method comprising: selecting a predetermined siRNA molecule having a functional group; and covalently bonding the siRNA molecule to a hydrophilic polymer.

9. The method according to claim 8 , wherein the covalently bonding comprises: activating the functional group of siRNA; and covalently bonding the activated functional group to a hydrophilic polymer.

10. The method according to claim 9 , wherein the functional group is selected from the group consisting of an amine group, thiol group, phosphate group and combinations thereof.

11. The method according to claim 9 , wherein the functional group of siRNA is activated using a material selected from the group consisting of 1-ethyl-3,3-diethylaminopropyl carbodiimide, imidazole, N-hydrosuccinimide, dichlorohexylcarbodiimide, N-β-maleimidopropionic acid, N-β-maleimidopropyloxylsuccinimide ester, and N-succinimidylpyridyldithio propionate.

12. The polyelectrolyte complex micelle according to claim 1 , wherein the siRNA decreases expression of a gene selected from the group consisting of bcl-2, vascular endothelial growth factor (VEGF), VEGF-B, VEGF-C, VEGF-D and PIGF.

Assignments (6)
MERGER Recorded Mar 28, 2022
From: SAMYANG BIOPHARMACEUTICALS CORPORATION
To: SAMYANG HOLDINGS CORPORATION
Reel/Frame 059413/0856 →
NUNC PRO TUNC ASSIGNMENT Recorded Mar 28, 2022
From: SAMYANG HOLDINGS CORPORATION
To: BIONEER CORPORATION; KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Reel/Frame 059414/0384 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 033773 FRAME 0479. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTION Recorded Sep 24, 2014
From: SAMYANG CORPORATION
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 033813/0485 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY'S ADDRESS PREVIOUSLY RECORDED AT REEL: 033773 FRAME: 0479. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 24, 2014
From: SAMYANG CORPORATION
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 033813/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2014
From: SAMYANG CORPORATION
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 033773/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2007
From: JEONG, JI HOON; PARK, TAE GWAN; KIM, SUN-HWA
To: BIONEER CORPORATION; SAMYANG CORPORATION; KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Reel/Frame 018776/0173 →
Continuity (2)
Continuation In Part 10551466
Related Publication 20070287681A1 · Dec 13, 2007